Tagged with UK

UK Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of his company. Unlike many of your peers, you are very optimistic about Brexit. What opportunities do you believe Brexit will…

Brexit The European Medicines Agency has cut Britain out of its contracts 7 months ahead of Brexit. “You might have been working on a cancer drug for decades and built up so much expertise that you are the absolute specialist in your field and now have to transfer all your knowledge…

GSK KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide…

UK Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure only two years ago after an MBO led by current CEO Kevin Cook, but its roots date back almost 50…

UK Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s platform and talks commercialisation. Can you please start by introducing Congenica to our international readers? “As well as disease diagnosis,…

UK Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities.     Let’s please start this interview by introducing the UK affiliate of Alexion to our audience. How would you describe the…

UK With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new chemical entity launches, after USA and Germany, despite the uncertainty created by Brexit. Furthermore, she highlights the fact that the…

Ipsen For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general manager for the UK and Ireland, Ewan McDowall, tells us the company’s focus remains on attracting and developing great talent,…

Brexit Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms ever closer, industry professionals fervently speculate on how it will affect the country’s position as one of the world’s great…

UK Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and establishing standards of care on a European level.   I see technology as the enabler that creates new possibilities. Imaging…

UK Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease. She speaks about possible care pathways of the future and international collaboration on research.   We also collaborate on workshops…

UK After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting exciting Phase III developments and introducing the new Baylab opened by Bayer in Reading (near London).   It is this…